Intellia’s regulatory path and numbers
- Intellia Therapeutics said April 27 it began a rolling FDA biologics application for lonvo-z after Phase 3 HAELO data in hereditary angioedema. - In the six-month primary period, lonvo-z cut monthly attack rates 87% versus placebo, while 62% of treated patients stayed attack-free. - RMAT status could speed review as Intellia targets a first-half 2027 U.S. launch. (ir.intelliatx.com)
CRISPR is a gene-editing tool that acts like molecular scissors, and Intellia is now asking the Food and Drug Administration to clear an infused version for hereditary angioedema. (ir.intelliatx.com) Hereditary angioedema is a rare inherited disease that causes sudden swelling in the face, airway, abdomen, and limbs when bradykinin levels rise too high. Lonvoguran ziclumeran, or lonvo-z, is designed to switch off the KLKB1 gene in the liver to keep kallikrein and bradykinin lower after one dose. (ir.intelliatx.com) Intellia said on April 27, 2026 that it started a rolling biologics license application, or BLA, for lonvo-z, the regulatory filing used for many complex biologic medicines. The company said it expects to finish that submission in the second half of 2026. (ir.intelliatx.com) The filing came the same day Intellia reported positive topline results from HAELO, its global Phase 3 trial in hereditary angioedema. The company said the study met its primary endpoint and all key secondary endpoints with favorable safety and tolerability data. (ir.intelliatx.com) In the six-month primary observation period, Intellia said lonvo-z reduced monthly attack rates by 87% versus placebo. It also said 62% of treated patients were attack-free and 81% remained free of chronic therapy during that period. (precisionmedicineonline.com) (ir.intelliatx.com) A rolling BLA lets a company submit sections of an application before the full package is complete, and Intellia said lonvo-z can use that route because the drug already has Regenerative Medicine Advanced Therapy designation. The company also said lonvo-z has Orphan Drug designation for hereditary angioedema. (ir.intelliatx.com 1) (ir.intelliatx.com 2) Intellia said it also took part in the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot, which is meant to help companies resolve factory and product-quality questions before filing. Those manufacturing details matter for gene-editing drugs because the product has to be made consistently before regulators will approve it. (ir.intelliatx.com) The company is preparing for a possible U.S. launch in the first half of 2027 if the FDA accepts the filing and approves the drug. If approved, Intellia said lonvo-z would become the first in vivo CRISPR-based gene-editing therapy on the market. (ir.intelliatx.com) The regulatory push comes with financing pressure. Intellia ended 2025 with about $605 million in cash, cash equivalents, and marketable securities, said that was enough into the second half of 2027, and on April 27 announced a $150 million common-stock offering. (marketscreener.com) (ir.intelliatx.com) Intellia’s next step is less about whether lonvo-z can cut attacks than whether the FDA is satisfied with the full application, manufacturing package, and review timeline. The company said the agency will decide after filing acceptance whether to grant priority review and set a target action date. (ir.intelliatx.com)
